Shares of Aduro Biotech Inc. (NASDAQ:ADRO) traded up 3.2% on Wednesday . The company traded as high as $14.76 and last traded at $14.71, with a volume of 140,689 shares. The stock had previously closed at $14.26.

A number of analysts have recently weighed in on the stock. Canaccord Genuity reiterated a “buy” rating on shares of Aduro Biotech in a report on Tuesday, May 3rd. FBR & Co restated a “buy” rating and issued a $34.00 price objective (up from $30.00) on shares of Aduro Biotech in a report on Saturday, May 14th. Leerink Swann restated a “buy” rating and issued a $48.00 price objective on shares of Aduro Biotech in a report on Thursday, May 5th. Roth Capital restated a “buy” rating and issued a $22.00 price objective on shares of Aduro Biotech in a report on Monday, July 11th. Finally, Zacks Investment Research lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Aduro Biotech presently has an average rating of “Hold” and a consensus target price of $24.17.

The firm’s 50-day moving average price is $12.22 and its 200 day moving average price is $13.59. The firm’s market capitalization is $964.64 million.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Monday, May 2nd. The company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.20. On average, analysts expect that Aduro Biotech Inc. will post ($1.24) EPS for the current fiscal year.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $11.61, for a total transaction of $290,250.00. Following the completion of the sale, the insider now directly owns 13,939 shares in the company, valued at approximately $161,831.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

An institutional investor recently bought a new position in Aduro Biotech stock. ProShare Advisors LLC purchased a new stake in shares of Aduro Biotech Inc. (NASDAQ:ADRO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 51,296 shares of the company’s stock, valued at approximately $1,443,000. ProShare Advisors LLC owned 0.08% of Aduro Biotech at the end of the most recent quarter.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.